We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Early Detection of Pseudomonas aeruginosa Increases Survival Chances

By Labmedica staff writers
Posted on 29 Jul 2008
A technique has been developed for the early detection of superbug Pseudomonas aeruginosa, which particularly infects patients with cystic fibrosis.

In the new diagnostic method, a non-colored compound reacts with an enzyme present in the bacteria and produces a very distinctive purple color. More...
The technique works on 99% of the strains P. aeruginosa.

The bacteria infect the fluid in the lungs of cystic fibrosis patients and also attack patients with localized and systemic immune defects, such as those suffering from burns, patients with AIDS, and cancer. P. aeruginosa accounts for 10% of all nosocomial infections, according to the Centers for Disease Control and Prevention in the United States (CDC; Atlanta, GA, USA).

The infections are difficult to treat because the bacteria are tolerant to many detergents, disinfectants, and antimicrobial compounds. They are especially difficult to control in hospitals and institutional environments and therefore hospital staff needs to diagnose the cause of the infections very quickly.

Researchers from the University of Sunderland (UK), the North Umbria University (Newcastle, UK), and bioMérieux, France
(Marcy l'Etoile) developed the technique that can identify Pseudomonas within 24-48 hours of infection, greatly increasing the patient's chances of survival.


Related Links:
Centers for Disease Control and Prevention in the United States
University of Sunderland
bioMérieux

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.